{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:04:55Z","timestamp":1792631095021,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adverse outcomes associated with the treatment of\n                    <jats:italic>Toxoplasma gondii<\/jats:italic>\n                    infections in patients with various health backgrounds have not been characterized. The aim of this study was to identify the adverse outcomes and adverse events associated with the current clinical treatments of\n                    <jats:italic>Toxoplama gondii<\/jats:italic>\n                    infections using real world data reported to the FDA adverse event reporting system (FAERS). Data submitted to FAERS between 2013 and 2019 was retrieved and analyzed. Reporting odds ratio of death was calculated for the drugs having\u2009\u2265\u200925 reports of adverse outcomes. The adverse event profiles for the same drugs were analyzed and the reporting odds ratio was calculated relative to all other drugs used in the treatment of\n                    <jats:italic>Toxoplasma<\/jats:italic>\n                    infections. There were 503 cases reporting the treatment of\n                    <jats:italic>Toxoplasma<\/jats:italic>\n                    infections in the FAERS database. Death (DE) was the adverse outcome in 102 reports, of which 23 (22.5%) anti-\n                    <jats:italic>Toxoplasma<\/jats:italic>\n                    drugs were listed as the primary suspect drug (PS). Clindamycin (2.04; 1.07\u20133.90) followed by pyrimethamine (1.53; 0.99\u20132.36) were the most likely to be associated with death. Adverse events analysis suggest that sulfonamides formulations may have a less favorable safety profile. Our study represents the first real-world analysis of adverse outcomes and events associated with the treatment of\n                    <jats:italic>Toxoplasma<\/jats:italic>\n                    infections. Our findings support the need to better understand the current first-line agents for\n                    <jats:italic>Toxoplasma<\/jats:italic>\n                    infections, in addition to underscoring the need to identify safer regimens.\n                  <\/jats:p>","DOI":"10.1038\/s41598-020-80569-7","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T06:26:43Z","timestamp":1610519203000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Adverse outcomes associated with the treatment of Toxoplasma infections"],"prefix":"10.1038","volume":"11","author":[{"given":"Ahmed M.","family":"Shammaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imaan","family":"Benmerzouga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"80569_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/B978-0-444-53490-3.00008-X","volume":"114","author":"SK Halonen","year":"2013","unstructured":"Halonen, S. K. & Weiss, L. M. Toxoplasmosis. Handb. Clin. Neurol. 114, 125\u2013145. https:\/\/doi.org\/10.1016\/B978-0-444-53490-3.00008-X (2013).","journal-title":"Handb. Clin. Neurol."},{"key":"80569_CR2","doi-asserted-by":"publisher","first-page":"e90203","DOI":"10.1371\/journal.pone.0090203","volume":"9","author":"J Flegr","year":"2014","unstructured":"Flegr, J., Prandota, J., Sovickova, M. & Israili, Z. H. Toxoplasmosis\u2014a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries. PLoS ONE 9, e90203. https:\/\/doi.org\/10.1371\/journal.pone.0090203 (2014).","journal-title":"PLoS ONE"},{"key":"80569_CR3","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1146\/annurev-micro-091014-104100","volume":"69","author":"IJ Blader","year":"2015","unstructured":"Blader, I. J., Coleman, B. I., Chen, C. T. & Gubbels, M. J. Lytic cycle of Toxoplasma gondii: 15 years later. Annu. Rev. Microbiol. 69, 463\u2013485. https:\/\/doi.org\/10.1146\/annurev-micro-091014-104100 (2015).","journal-title":"Annu. Rev. Microbiol."},{"key":"80569_CR4","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","volume":"363","author":"JG Montoya","year":"2004","unstructured":"Montoya, J. G. & Liesenfeld, O. Toxoplasmosis. Lancet 363, 1965\u20131976. https:\/\/doi.org\/10.1016\/S0140-6736(04)16412-X (2004).","journal-title":"Lancet"},{"key":"80569_CR5","doi-asserted-by":"publisher","first-page":"e1006351","DOI":"10.1371\/journal.ppat.1006351","volume":"13","author":"OA Mendez","year":"2017","unstructured":"Mendez, O. A. & Koshy, A. A. Toxoplasma gondii: Entry, association, and physiological influence on the central nervous system. PLoS Pathog. 13, e1006351. https:\/\/doi.org\/10.1371\/journal.ppat.1006351 (2017).","journal-title":"PLoS Pathog."},{"key":"80569_CR6","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00057-17","author":"IR Dunay","year":"2018","unstructured":"Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O. & Montoya, J. G. Treatment of toxoplasmosis: Historical perspective, animal models, and current clinical practice. Clin. Microbiol. Rev. https:\/\/doi.org\/10.1128\/CMR.00057-17 (2018).","journal-title":"Clin. Microbiol. Rev."},{"key":"80569_CR7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40268-017-0206-8","volume":"17","author":"RR Ben-Harari","year":"2017","unstructured":"Ben-Harari, R. R., Goodwin, E. & Casoy, J. Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: A systematic review. Drugs R D 17, 523\u2013544. https:\/\/doi.org\/10.1007\/s40268-017-0206-8 (2017).","journal-title":"Drugs R D"},{"key":"80569_CR8","doi-asserted-by":"publisher","first-page":"e00036","DOI":"10.1016\/j.fawpar.2019.e00036","volume":"15","author":"N Konstantinovic","year":"2019","unstructured":"Konstantinovic, N., Guegan, H., Stajner, T., Belaz, S. & Robert-Gangneux, F. Treatment of toxoplasmosis: Current options and future perspectives. Food Waterborne Parasitol. 15, e00036. https:\/\/doi.org\/10.1016\/j.fawpar.2019.e00036 (2019).","journal-title":"Food Waterborne Parasitol."},{"key":"80569_CR9","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1016\/j.clinthera.2008.10.021","volume":"30","author":"B Iaccheri","year":"2008","unstructured":"Iaccheri, B. et al. Adverse drug reactions to treatments for ocular toxoplasmosis: A retrospective chart review. Clin. Ther. 30, 2069\u20132074. https:\/\/doi.org\/10.1016\/j.clinthera.2008.10.021 (2008).","journal-title":"Clin. Ther."},{"key":"80569_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/trstmh\/try040","volume":"112","author":"L Guaraldo","year":"2018","unstructured":"Guaraldo, L. et al. Ocular toxoplasmosis: Adverse reactions to treatment in a Brazilian cohort. Trans. R. Soc. Trop. Med. Hyg. 112, 188\u2013192. https:\/\/doi.org\/10.1093\/trstmh\/try040 (2018).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"80569_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"80569_CR12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1046\/j.1525-1497.2003.20130.x","volume":"18","author":"SR Ahmad","year":"2003","unstructured":"Ahmad, S. R. Adverse drug event monitoring at the food and drug administration. J. Gen. Intern. Med. 18, 57\u201360. https:\/\/doi.org\/10.1046\/j.1525-1497.2003.20130.x (2003).","journal-title":"J. Gen. Intern. Med."},{"key":"80569_CR13","doi-asserted-by":"publisher","first-page":"160026","DOI":"10.1038\/sdata.2016.26","volume":"3","author":"JM Banda","year":"2016","unstructured":"Banda, J. M. et al. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data 3, 160026. https:\/\/doi.org\/10.1038\/sdata.2016.26 (2016).","journal-title":"Sci Data"},{"key":"80569_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/DDDT.S60973","volume":"11","author":"PH Alday","year":"2017","unstructured":"Alday, P. H. & Doggett, J. S. Drugs in development for toxoplasmosis: Advances, challenges, and current status. Drug Des. Dev. Ther. 11, 273\u2013293. https:\/\/doi.org\/10.2147\/DDDT.S60973 (2017).","journal-title":"Drug Des. Dev. Ther."},{"key":"80569_CR15","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.cgh.2017.11.025","volume":"16","author":"V Chedid","year":"2018","unstructured":"Chedid, V., Vijayvargiya, P. & Camilleri, M. Advantages and limitations of the federal adverse events reporting system in assessing adverse event reporting for eluxadoline. Clin. Gastroenterol. Hepatol. 16, 336\u2013338. https:\/\/doi.org\/10.1016\/j.cgh.2017.11.025 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"80569_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1179\/2047773213Y.0000000094","volume":"107","author":"S Rajapakse","year":"2013","unstructured":"Rajapakse, S., Chrishan Shivanthan, M., Samaranayake, N., Rodrigo, C. & Deepika, F. S. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog. Glob. Health 107, 162\u2013169. https:\/\/doi.org\/10.1179\/2047773213Y.0000000094 (2013).","journal-title":"Pathog. Glob. Health"},{"key":"80569_CR17","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1503\/cmaj.111152","volume":"183","author":"JM Ho","year":"2011","unstructured":"Ho, J. M. & Juurlink, D. N. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ 183, 1851\u20131858. https:\/\/doi.org\/10.1503\/cmaj.111152 (2011).","journal-title":"CMAJ"},{"key":"80569_CR18","doi-asserted-by":"publisher","first-page":"e0185654","DOI":"10.1371\/journal.pone.0185654","volume":"12","author":"A Fukuda","year":"2017","unstructured":"Fukuda, A. et al. Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. PLoS ONE 12, e0185654. https:\/\/doi.org\/10.1371\/journal.pone.0185654 (2017).","journal-title":"PLoS ONE"},{"key":"80569_CR19","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/clinids\/21.3.656","volume":"21","author":"E Caumes","year":"1995","unstructured":"Caumes, E. et al. Adverse cutaneous reactions to pyrimethamine\/sulfadiazine and pyrimethamine\/clindamycin in patients with AIDS and toxoplasmic encephalitis. Clin. Infect. Dis. 21, 656\u2013658. https:\/\/doi.org\/10.1093\/clinids\/21.3.656 (1995).","journal-title":"Clin. Infect. Dis."},{"key":"80569_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/s0002-9394(02)01537-4","volume":"134","author":"LH Bosch-Driessen","year":"2002","unstructured":"Bosch-Driessen, L. H. et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am. J. Ophthalmol. 134, 34\u201340. https:\/\/doi.org\/10.1016\/s0002-9394(02)01537-4 (2002).","journal-title":"Am. J. Ophthalmol."},{"key":"80569_CR21","doi-asserted-by":"publisher","first-page":"281","DOI":"10.4103\/0974-777X.83536","volume":"3","author":"JM Furtado","year":"2011","unstructured":"Furtado, J. M., Smith, J. R., Belfort, R. Jr., Gattey, D. & Winthrop, K. L. Toxoplasmosis: A global threat. J. Glob. Infect. Dis. 3, 281\u2013284. https:\/\/doi.org\/10.4103\/0974-777X.83536 (2011).","journal-title":"J. Glob. Infect. Dis."},{"key":"80569_CR22","doi-asserted-by":"publisher","first-page":"501","DOI":"10.2471\/BLT.12.111732","volume":"91","author":"PR Torgerson","year":"2013","unstructured":"Torgerson, P. R. & Mastroiacovo, P. The global burden of congenital toxoplasmosis: A systematic review. Bull. World Health Organ 91, 501\u2013508. https:\/\/doi.org\/10.2471\/BLT.12.111732 (2013).","journal-title":"Bull. World Health Organ"},{"key":"80569_CR23","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1128\/IAI.61.4.1596-1598.1993","volume":"61","author":"Y Welker","year":"1993","unstructured":"Welker, Y. et al. Interaction between human immunodeficiency virus and Toxoplasma gondii replication in dually infected monocytoid cells. Infect. Immun. 61, 1596\u20131598. https:\/\/doi.org\/10.1128\/IAI.61.4.1596-1598.1993 (1993).","journal-title":"Infect. Immun."},{"key":"80569_CR24","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1046\/j.1365-2249.2002.01941.x","volume":"129","author":"M Alfonzo","year":"2002","unstructured":"Alfonzo, M. et al. Temporary restoration of immune response against Toxoplasma gondii in HIV-infected individuals after HAART, as studied in the hu-PBMC-SCID mouse model. Clin. Exp. Immunol. 129, 411\u2013419. https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01941.x (2002).","journal-title":"Clin. Exp. Immunol."},{"key":"80569_CR25","doi-asserted-by":"publisher","first-page":"11496","DOI":"10.1038\/s41598-017-10675-6","volume":"7","author":"HM Ngo","year":"2017","unstructured":"Ngo, H. M. et al. Toxoplasma modulates signature pathways of human epilepsy neurodegeneration & cancer. Sci. Rep. 7, 11496. https:\/\/doi.org\/10.1038\/s41598-017-10675-6 (2017).","journal-title":"Sci. Rep."},{"key":"80569_CR26","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1128\/aac.44.9.2575-2577.2000","volume":"44","author":"F Derouin","year":"2000","unstructured":"Derouin, F. & Santillana-Hayat, M. Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro. Antimicrob. Agents Chemother. 44, 2575\u20132577. https:\/\/doi.org\/10.1128\/aac.44.9.2575-2577.2000 (2000).","journal-title":"Antimicrob. Agents Chemother."},{"key":"80569_CR27","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1128\/AAC.02009-15","volume":"59","author":"AJ Neville","year":"2015","unstructured":"Neville, A. J. et al. Clinically available medicines demonstrating anti-toxoplasma activity. Antimicrob. Agents Chemother. 59, 7161\u20137169. https:\/\/doi.org\/10.1128\/AAC.02009-15 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"80569_CR28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/pds.3805","volume":"24","author":"CK Wong","year":"2015","unstructured":"Wong, C. K., Ho, S. S., Saini, B., Hibbs, D. E. & Fois, R. A. Standardisation of the FAERS database: A systematic approach to manually recoding drug name variants. Pharmacoepidemiol. Drug Saf. 24, 731\u2013737. https:\/\/doi.org\/10.1002\/pds.3805 (2015).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"80569_CR29","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13, 519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"80569_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1128\/MMBR.00027-15","volume":"79","author":"KJ Pittman","year":"2015","unstructured":"Pittman, K. J. & Knoll, L. J. Long-term relationships: The complicated interplay between the host and the developmental stages of Toxoplasma gondii during acute and chronic infections. Microbiol. Mol. Biol. Rev. 79, 387\u2013401. https:\/\/doi.org\/10.1128\/MMBR.00027-15 (2015).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"80569_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","volume":"32","author":"E Lopez-Gonzalez","year":"2009","unstructured":"Lopez-Gonzalez, E., Herdeiro, M. T. & Figueiras, A. Determinants of under-reporting of adverse drug reactions: A systematic review. Drug Saf. 32, 19\u201331. https:\/\/doi.org\/10.2165\/00002018-200932010-00002 (2009).","journal-title":"Drug Saf."},{"key":"80569_CR32","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman, K. B., Dimbil, M., Erdman, C. B., Tatonetti, N. P. & Overstreet, B. M. The weber effect and the united states food and drug administration\u2019s adverse event reporting system (FAERS): Analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 37, 283\u2013294. https:\/\/doi.org\/10.1007\/s40264-014-0150-2 (2014).","journal-title":"Drug Saf."},{"key":"80569_CR33","doi-asserted-by":"publisher","first-page":"864","DOI":"10.7150\/ijms.5892","volume":"10","author":"K Yoshimura","year":"2013","unstructured":"Yoshimura, K. et al. A survey of the FAERS database concerning the adverse event profiles of alpha1-adrenoreceptor blockers for lower urinary tract symptoms. Int. J. Med. Sci. 10, 864\u2013869. https:\/\/doi.org\/10.7150\/ijms.5892 (2013).","journal-title":"Int. J. Med. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80569-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80569-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80569-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T20:49:47Z","timestamp":1670014187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80569-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80569"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80569-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,13]]},"assertion":[{"value":"29 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1035"}}